Chewable tablets are a versatile dosage form offering several advantages including oral drug delivery without the need for water, ease of swallowing, the stability advantages of solid dosage forms, ...

New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options SAN CARLOS, Calif., June 11, ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA® ...

February 16, 2010 — The US Food and Drug Administration (FDA) has approved a new tablet formulation for the protease inhibitor ritonavir (Norvir, Abbott Laboratories, Inc) in combination with other ...

Notes: Safety population, includes all randomized subjects who received at least one dose of study drug or placebo. Based on the encouraging weight loss, as well as the safety and tolerability results ...

SAN CARLOS, Calif., August 21, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the ...